EUVIMEDEUVIMED entdecken
Crossref

Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis

Franziska Maria Kraus, Alexander Traut, Georg Nilius, Jan Volmerig, Andreas Koziorowski, Imke Stöver, Florian Grabellus, Michael Stahl, Daniel C Christoph

Oncology · 2024

DOI: 10.1159/000540515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Franziska Maria Kraus und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany, franzi_kraus@gmx.de. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Thyroid Nuclear Factor 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pulmonary adenocarcinoma with enteric differentiation (PAED) without thyroid transcription factor-1 (TTF-1) expression is an extremely rare variant of lung cancer. Due to its rarity, few clinicopathological and molecular studies have been performed on PAED, particularly in Caucasian patients. Therefore, it is necessary to obtain clinicopathological data of Caucasian PAED patients without TTF-1 expression, their systemic therapy options, and the efficacy of their systemic treatment.

Methods

We examined the clinicopathological features of 121 cases of TTF-1-negative pulmonary adenocarcinoma at a certified German lung cancer center including 79 cases without a PAED and 42 cases with a PAED, compared these subgroups, and investigated patients’ response to chemotherapy and immunotherapy as first-line treatment. By using endoscopy and/or a PET-CT, a primary adenocarcinoma of the digestive tract was excluded in all PAED patients.

Results

A comparison of clinicopathological data of TTF-1-negative PAED and non-PAED patients revealed a significantly lower frequency of high programmed death receptor ligand 1 (PD-L1) expression in PAED resulting in the lack of single-agent immunotherapy (p = 0.032) in this subgroup. Frequencies of an activating Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutation were high in both groups (46.7% and 50.0%), but G12C gene mutations were seldomly noted (in 6.7% and 18.5% of patients with evaluable data). Median overall survival (OS) was poor in both groups (10 and 12 months). The majority of PAED patients received platinum-based and taxane-containing chemotherapy or chemo-/immunotherapy with an objective response rate (ORR) of 31.6% and a disease control rate of 57.9%. Median progression-free survival (PFS) and OS of PAED patients with systemic therapy were very poor (3.9 months and 5.9 months).

Conclusions

Caucasian patients with TTF-1 negative PAED have a poor prognosis with a reduced ORR to standard first-line systemic therapy and short survival times (PFS and OS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungThyroid Nuclear Factor 1HumansMaleFemaleMiddle AgedAgedPrognosisAged, 80 and overAdultProto-Oncogene Proteins p21(ras)B7-H1 AntigenDNA-Binding ProteinsTranscription Factors

Stichwörter der Autor:innen

Clinicopathological featuresPrognosisPulmonary adenocarcinoma with enteric differentiationTTF-1-negative pulmonary adenocarcinoma

Substanzen

Thyroid Nuclear Factor 1NKX2-1 protein, humanProto-Oncogene Proteins p21(ras)B7-H1 AntigenKRAS protein, humanTTF1 protein, humanCD274 protein, humanDNA-Binding ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Medical Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany, franzi_kraus@gmx.de.
  • Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
  • Department of Pneumology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
  • Germany and University Hospital Witten-Herdecke, Witten, Germany.
  • Department of Thoracic Surgery, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
  • Practice for Radio-Oncology Essen, Essen, Germany.

Zitieren

APA

Kraus, F. M., Traut, A., Nilius, G., Volmerig, J., Koziorowski, A., Stöver, I., Grabellus, F., Stahl, M., & Christoph, D. C. (2024). Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis. Oncology. https://doi.org/10.1159/000540515

Vancouver

Kraus FM, Traut A, Nilius G, Volmerig J, Koziorowski A, Stöver I, et al. Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis. Oncology. 2024. doi:10.1159/000540515

BibTeX
@article{Kraus2024,
  author = {Kraus, Franziska Maria and Traut, Alexander and Nilius, Georg and Volmerig, Jan and Koziorowski, Andreas and Stöver, Imke and Grabellus, Florian and Stahl, Michael and Christoph, Daniel C},
  title = {Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000540515}
}
Kostenlos starten →